Facebook disapproved your peptide ads, and you are trying to figure out the fastest route back to a live campaign. Disapproval is different from a full account suspension, but it still stops your campaigns cold. Disapproved ads can be fixed and resubmitted, while suspensions require a full account-level appeal.
We have handled dozens of disapproval cases for compounding pharmacies and peptide clinics. The process for getting ads approved again is straightforward if you know exactly what Facebook is looking for. In most cases, the fix involves adjusting your ad copy, updating your landing page, and submitting the right documentation.
Why Facebook Disapproves Peptide Ads
Facebook's automated review system scans ad components against its Advertising Policies, specifically those covering health and wellness products. Peptides fall under restricted substances and healthcare categories, which means they face higher scrutiny than standard consumer ads.
The most common disapproval reasons we encounter are claims about weight loss or muscle growth without substantiation, imagery that appears clinical or medical in nature, landing pages that sell products requiring a prescription, and missing disclaimers about compounding or supplement status. Ads referencing brand-name drugs like Ozempic or Mounjaro are almost always disapproved on first review.
Regulatory Standards You Need to Know
FDA 503A governs compounded drugs prepared by licensed pharmacists for individual patients. If you are advertising compounded peptides, your ads must not make claims that go beyond what 503A allows. FDA 503B covers outsourcing facilities that compound sterile products at scale, with the same advertising restrictions applying. Both frameworks require that you advertise a service, not a product.
DSHEA 1994 is relevant if your peptides are marketed as dietary supplements. It prohibits disease treatment claims and requires accurate labeling. Facebook's policy team often cross-references your ad language against these federal standards before approving or disapproving.
The BAV appeal pathway is your primary tool for challenging disapprovals. Facebook requires verified business information before it will allow peptide-related advertising at scale. The verification process involves submitting your business license, pharmacy license, and domain ownership documentation.
Steps to Fix Disapproved Ads
Identify the specific policy violation. Facebook tells you which policy your ad violated in the disapproval notice. Click through to the detail view and note the exact policy section. Different policies require different fixes, so knowing the specific trigger saves time.
Remove health claims from copy and landing pages. Check every headline, description, and image for implied health outcomes. Switch to educational language that describes what the product is, not what it does to the body.
Update your landing page. Add a clear disclaimer that your products are compounded under FDA 503A or 503B regulations. Include a link to your pharmacy license if applicable. Make sure your terms of service clarify that you do not make medical claims.
Resubmit with documentation. When you request a review, attach documentation that proves compliance. Pharmacy licenses, business registrations, and a written compliance summary all help speed up the manual review process.
Case Study: Disapproval Resolved in 48 Hours
A peptide clinic client had 8 ads disapproved for claiming weight loss outcomes. Their headlines included phrases like drop 20 pounds with our peptide protocol. We rewrote the copy to focus on compounded peptide availability and consultation services. We added 503A compliance language to the landing page and submitted a BAV appeal. All 8 ads were approved within 48 hours of resubmission.
Related articles
Compounding Pharmacy Ads Banned
Ready to run these ads? Book a call at calendly.com/custodio-2/30min